IPS HEART is the first induced pluripotent stem cell company to launch in 2014 around heart disease. With over $20 million+ of funded research, we were the first to publish our moon-shot approach showing extensive heart regeneration after heart attack with over 50%+ EF improvement vs control and a 70% reduction in fibrosis. We have created extensive new functional human heart muscle in our published studies thus validating our patented IPS small molecule platform approach. With a completed FDA PRE-IND meeting and GMP manufacturing, we plan to file the first IPS IND to start clinically in the United States.
IPS HEART replicated its pioneering small molecule IPS platform approach in a second disease by publishing for the first time new dystrophin + skeletal muscle for Duchenne Muscular Dystrophy.
IPS HEART is the only IPS company to have published strong efficacy in two difficult diseases by creating new cardiac muscle and skeletal muscle for both heart disease and DMD.